Amarin lays off US sales­force, names new CEO in shake­up

The new crew in charge at Amarin has out­lined their plans to turn things around — and it in­volves a sweep­ing re­org.

Amarin will cut all US sales po­si­tions and 30% of non-sales roles, while re­tain­ing a lim­it­ed team to sup­port Vas­cepa, its phar­ma­ceu­ti­cal-grade fish oil de­riv­a­tive. In­stead, it will fo­cus on reach­ing more pa­tients in Eu­rope (where the drug is mar­ket­ed as Vazkepa) as well as oth­er in­ter­na­tion­al mar­kets. Patrick Holt is step­ping in as pres­i­dent and CEO, re­plac­ing in­ter­im chief Aaron Berg, who will stay on as EVP and pres­i­dent in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER